SYRE Spyre Therapeutics Inc.

Price (delayed)

$88.17

Market cap

$7.77B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.99

Enterprise value

$7.61B

?
Relative Growth: Rel. Growth: 13
Relative Strength: Rel. Strength: 98
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 12

In June 2023, Aeglea completed its asset acquisition of Spyre Therapeutics, Inc. and shifted its disease focus to IBD. Aeglea is advancing a pipeline of antibody therapeutics with the potential ...

Highlights
Spyre Therapeutics's quick ratio has surged by 185% YoY and by 108% QoQ
The company's equity has surged by 142% YoY and by 64% QoQ

Key stats

What are the main financial stats of SYRE

SYRE stock price

How has the Spyre Therapeutics stock price performed over time
Intraday
-4.13%
1 week
-3.29%
1 month
-17.2%
1 year
450.37%
YTD
169.14%
QTD
-0.69%

Financial performance

How have Spyre Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$201.34M
Net income
-$178.92M
Gross margin
N/A
Net margin
N/A
The net income has increased by 13% year-on-year
Spyre Therapeutics's operating income has increased by 5% YoY

Price vs fundamentals

How does SYRE's price correlate with its fundamentals

Growth

What is Spyre Therapeutics's growth rate over time

Valuation

What is Spyre Therapeutics stock price valuation
P/E
N/A
P/B
6.95
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
SYRE's EPS is up by 32% YoY and by 6% QoQ
SYRE's P/B is 150% above its 5-year quarterly average of 2.9 and 54% above its last 4 quarters average of 4.7
The company's equity has surged by 142% YoY and by 64% QoQ

Efficiency

How efficient is Spyre Therapeutics business performance
The company's return on equity rose by 48% YoY and by 22% QoQ
SYRE's return on invested capital is up by 46% year-on-year and by 23% since the previous quarter
Spyre Therapeutics's ROA has increased by 43% YoY and by 20% from the previous quarter

Dividends

What is SYRE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SYRE.

Financial health

How did Spyre Therapeutics financials performed over time
SYRE's current ratio has soared by 186% YoY and by 107% QoQ
Spyre Therapeutics's quick ratio has surged by 185% YoY and by 108% QoQ
Spyre Therapeutics's debt is 100% lower than its equity
The company's equity has surged by 142% YoY and by 64% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.